Is ASSEMBLY BIOSCIENCES, INC. (ASMB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.7% / 30% | 25.1% / 30% | 0.0% / 30% | 19.54% / 5% | ✗ NOT HALAL |
| DJIM | 0.7% / 33% | 25.1% / 33% | 0.0% / 33% | 19.54% / 5% | ✗ NOT HALAL |
| MSCI | 2.6% / 33% | 94.1% / 33% | 0.0% / 33% | 19.54% / 5% | ✗ NOT HALAL |
| S&P | 0.7% / 33% | 25.1% / 33% | 0.0% / 33% | 19.54% / 5% | ✗ NOT HALAL |
| FTSE | 2.6% / 33% | 94.1% / 33% | 0.0% / 50% | 19.54% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 10.4% | |
| Operating Margin | 46.6% | |
| Net Margin | -8.5% | |
| Return on Equity (ROE) | -5.1% | |
| Return on Assets (ROA) | -4.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$51M |
| Free Cash Flow | -$51M |
| Total Debt | $3M |
| Debt-to-Equity | 1.3 |
| Current Ratio | 5.2 |
| Total Assets | $119M |
Price & Trading
| Last Close | $28.87 |
| 50-Day MA | $28.00 |
| 200-Day MA | $26.88 |
| Avg Volume | 100K |
| Beta | 1.2 |
|
52-Week Range
$7.75
| |
About ASSEMBLY BIOSCIENCES, INC. (ASMB)
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ASSEMBLY BIOSCIENCES, INC. (ASMB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ASSEMBLY BIOSCIENCES, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ASSEMBLY BIOSCIENCES, INC.'s debt ratio?
ASSEMBLY BIOSCIENCES, INC.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.6%.
What are ASSEMBLY BIOSCIENCES, INC.'s key financial metrics?
ASSEMBLY BIOSCIENCES, INC. has a market capitalization of $439M, and revenue of $29M. The company maintains a gross margin of 10.4% and a net margin of -8.5%. Return on equity stands at -5.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.